Dorzolamide/timolol combination has hypotensive and haemodynamic effects

Article

A fixed combination of dorzolamide and timolol significantly increase blood flow at the neuroretinal rim, demonstrating a combination of hypotensive and haemodynamic effects.

A fixed combination of dorzolamide and timolol significantly increase blood flow at the neuroretinal rim, demonstrating a combination of hypotensive and haemodynamic effects, according to a report published online ahead of print by Eye.

Teresa Rolle and colleagues from the University of Torino, Italy compared the effect of dorzolamide hydrochloride 2%, timolol maleate 0.5% and their fixed combination on intraocular pressure (IOP) and retinal and optic nerve head haemodynamics in 28 patients with primary open angle glaucoma.

After a four-week wash-out period, patients were randomized into two groups: group 1 received dorzolamide 2% monotherapy and group 2 received timolol 0.5% monotherapy. Following this period, both groups switched to a fixed combination of the two drugs for four-weeks. IOP, ocular diastolic perfusion pressure (ODPP), heart rate and scanning laser Doppler flowmetry measurements at the peripapillary retina and neuroretinal rim were taken at enrolment (T0), wash-out (T1), during monotherapy (T3) and during combination therapy (T4).

At T1 and T3, IOP had decreased significantly in group 1 (p<0.001) and in group 2 (p<0.001). At the same intervals, blood flow increased significantly at rim level in group 1 (p<0.05). Between intervals of T1 and T3, a significant increase in ODPP was observed in both groups.

The authors of this study believe that a fixed combination of dorzolamide and timolol significantly increases blood flow at the neuroretinal rim.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jay Chhablani, MD, shares late-breaking data from the ArMaDa trial, investigating gene therapy for Geographic Atrophy and dry age-related macular degeneration, at EURETINA
Editorial advisory board member Alexandra Miere, MD, PhD, speaks about the ACTOR and HERMES studies at the 2025 European Society of Retina Specialists (EURETINA) Congress
María Berrocal, MD, speaks about the Vit-Buckle Society symposium hosted at the 2025 European Society of Retina Specialists (EURETINA) annual meeting
© 2025 MJH Life Sciences

All rights reserved.